Kornimate/medical-research-clean huggingface dataset:
perturbation training reduces falls in people with ad

Conditions: Alzheimer Disease

Summary: this study will examine the overall capacity of people with alzheimer's disease learning fall-resistant skills from perturbation training.

falls can cause injury and death in older adults. those with alzheimer's disease are at an even higher fall risk. our goal is to test if people with mild alzheimer's disease can learn fall prevention skills from the exposure to large-scale perturbations on a treadmill. two groups with mild alzheimer's disease will be enrolled. one group will attend a perturbation training session while the other group receives no training. groups will then be exposed to perturbations on the ground immediately and three or six months after the training. over six months after the training, daily-living falls will be tracked for both groups. the falls following the perturbations in the lab and daily-living all-cause falls will be compared between groups to test our specific aims: 1) to test if people with alzheimer's disease can adapt to large-scale external perturbations and learn fall resistant motor skills; 2) to inspect whether people with alzheimer's disease can retain motor skills learned in aim 1; and 3) to determine if people with alzheimer's disease can generalize fall resistant skills to different contexts (treadmill to overground, inside the lab to outside the lab).

Eligibility criteria:
inclusion criteria: * participants must be at least 65 years old; * participants have a clinical diagnosis of probable ad; * participants can read and understand english; * participants must be able to walk independently at least 25 feet; * participants must be able to stand independently for at least 30 seconds; * participants must have a monteral cognitive assessment score of 11-21 or mini mental status examination score between 18 and 23. exclusion criteria: * individuals have ever experienced perturbation training; * individuals have hypotension or uncontrolled hypertension; * individuals exhibit osteoporosis; * participants suffer from coexisting psychiatric disorders, or other neurological conditions, or injuries, etc.
a national prospective cohort of patients with idiopathic nephrotic syndrome beginning in childhood.

Conditions: Idiopathic Nephrotic Syndrome

Summary: pediatric idiopathic nephrotic syndrome (ins) is a rare disease for which the optimal therapeutic strategy has not yet been defined. a network of clinicians treating complicated forms of this disease (grouped within the société de néphrologie pédiatrique, snp) exists, but to date there is no prospective cohort following up these patients that would facilitate the development of cohort-nested trials. this absence of structured follow up makes it difficult to set up prospective studies. the main objective is to create a prospective cohort of pediatric ins patients to collect cases treated in snp centers, to study their epidemiological characteristics, and to provide a basis for comparison for future cohort-nested trials.

in this study, data from patients with ins will be recorded prospectively, regularly and systematically. the cohort will be composed of patients followed by pediatric nephrologists affiliated with the snp. metropolitan france, reunion island and mayotte are the geographical areas concerned. it is planned to integrate other french overseas departments and territories, in particular the west indies. this is therefore a prospective, multicenter, cohort follow-up study. the data will be centralized via a secure website dedicated to the study. data will be obtained from: * medical record data (hospitalization/consultations) as part of routine clinical follow-up for patients with active disease. this information will be medically validated and integrated into the database with the help of clinical research staff. * a telephone interview for annual follow-ups for patients whose absence of active disease no longer requires a systematic medical visit. this structured interview will be administered by telephone by the study's clinical research staff. * self-administered or hetero-administered quality of life questionnaires (peds-ql), self-administered or hetero-administered treatment compliance questionnaires (morisky's score), and questionnaires on the aesthetic impact of treatments (ferriman's score). these questionnaires will be centralized and reported to the database by the study's clinical research staff.

Eligibility criteria:
inclusion criteria: * patient under 18 years of age * with idiopathic nephrotic syndrome (according to spn criteria) beginning after january 1, 2018 * child seen at least once in consultation or hospitalization by a pediatrician member of the society of pediatric nephrology * residing in france * consent signed by parents and patient's agreement to participate (if of age) * affiliated to a social security system. exclusion criteria: * refusal of the patient or legal representatives to participate in the cohort

Keywords: cohort - idiopathic nephrotic syndrome - child
effect of minimally invasive surgical assisted by robots on intraventricular hemorrhage

Conditions: Clarify the Therapeutic Differences Between Robot Assisted Endoscopic Clearance and Traditional Puncture and External Drainag

Summary: clarify the therapeutic differences between robot assisted endoscopic clearance and traditional puncture and external drainage, and establish a new minimally invasive surgical diagnosis and treatment strategy for intraventricular hemorrhage


Eligibility criteria:
inclusion criteria: * age range from 18 to 80 years old; * the time from onset to first ct confirmation of intraventricular hemorrhage is less than 24 hours; * before enrollment, ct confirmed that the intraventricular hemorrhage score (modified graeb score) was ≥ 8 points, and the total score of bilateral lateral ventricles was ≥ 5 points; * if there is concurrent cerebral hemorrhage but the hematoma volume is less than 30ml; ⑤ first ct to surgery time\<72 hours; ⑥ gcs ≤ 14. exclusion criteria: * ① suspected (unless excluded by angiography or cta/mra/mri) or untreated rupture of cerebral aneurysm, moyamoya disease, intracranial avm rupture, or tumor; * patients with a gcs score of 3 and/or fixed dilated pupils and/or no spontaneous breathing; * patients with pre-existing neurological disorders that affect neurological function assessment prior to onset; * coagulation dysfunction; * patients who require long-term anticoagulant treatment; ⑥ use dabigatran, apixaban, and/or rivaroxaban (or drugs of the same class) before symptoms appear; ⑦ platelet count\ 1.4; ⑧ pregnancy (positive serum or urine pregnancy test); ⑨ subtentorial hemorrhage or brainstem hemorrhage; ⑩ patients who have previously participated in other interventional clinical studies and participated in observational, natural history, and/or epidemiological studies that do not involve intervention are eligible; ⑪ subjects who are expected to not survive until the 180th day of visit; no written informed consent was given by the subjects or legal representatives.
in stent elutes study

Conditions: Coronary Artery Disease

Summary: this trial will compare the long term safety and effectiveness of the v flex plus ptx drug eluting coronary stent with conventional treatment for in-stent restenosis for coronary arteries.


Eligibility criteria:
inclusion criteria: * patient has given informed consent * patient has target lesion in native coronary artery or coronary bypass graft * patient has in-stent restenosis \>60% * patient has reference artery diameter 2.7-3.5 * patient agrees to return for clinical assessment at 1, 6, 9, 12 and 24 months and for a treadmill test at 9 months and an angiogram at 9 months and 24 months. exclusion criteria: * patient is less than 18 years of age * patient is pregnant or breast feeding * patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions. * patient is simultaneously participating in another investigative interventional cardiovascular drug or device study. * patient has known hypersensitivity or contraindication to aspirin or stainless steel or a sensitivity to contrast agent.

Keywords: coronary artery stent drug eluting patency restenosis
treatment of infected dialysis catheters with fiber optic ultraviolet light

Conditions: Catheter-Related Infections

Summary: this study is a first-in-man clinical trial using fiber optically delivered ultraviolet light for reducing viable bacteria within indwelling tunneled dialysis catheters.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * have the ability to provide informed consent * have an implanted dialysis catheter of one of the following models: medcomp titan 15.5f x 24 cm or medcomp titan 15.5f x 28 cm * positive blood culture drawn from the catheter exclusion criteria: * previous inclusion in study * pregnant
dose response relationship for single doses of corticotropin releasing hormone (crh) in normal volunteers and in patients with adrenal insufficiency

Conditions: Adrenal Gland Hyperfunction; Adrenal Gland Hypofunction; Cushing's Syndrome; Healthy

Summary: corticotropin releasing hormone (crh) is a hypothalamic hormone made up of 41 amino acids. amino acids are proteins that when combined make up different substances, like hormones. the order of amino acids in crh, has been determined, meaning that the hormone can now be synthetically reproduced in a laboratory setting. when crh is released from the hypothalamus it stimulates the pituitary gland to secrete another hormone, acth. acth then causes the adrenal glands to make a third hormone, cortisol. this process is known as the hypothalamic-pituitary-adrenal axis. problems can occur in any of the steps of this process and result in a variety of diseases (cushing's syndrome and adrenal insufficiency). researchers hope that crh created in a laboratory setting, ovine crh (ocrh) can be used to help diagnose and treat conditions of the hpa axis. this study will test the relationship for single doses of ocrh in normal volunteers and patients with disorders of the hpa axis. the ocrh will be injected into the patients vein as a single injection or slowly through an iv line over 24 hours. the participants will have blood tests taken to measure hormone levels before, during, and after receiving the ocrh.

corticotropin-releasing hormone (crh) is a 41 amino acid hypothalamic peptide whose chemical structure has recently been determined after more than two decades of intensive research. this peptide stimulates secretion of acth by the corticotroph cells of the pituitary gland. as with the previously discovered hypothalamic hormones, crh has important diagnostic and therapeutic applications. this study seeks to explore these clinical applications by determining the dose-response relationship for single doses of ovine crh (ocrh) in normal volunteers and in patients with disorders of the hypothalamic-pituitary-adrenal axis. crh is administered intravenously at doses up to 10 pg/kg, given as a bolus or up to 1 ug/kg/b as a continuous infusion lasting up to 24 hours. plasma levels of acth, cortisol and crh are measured before, during and after crh administration.

Eligibility criteria:
inclusion criteria: the normal volunteers are obtained through the nih volunteer program or are nih employees. normal volunteers are in excellent health and are receiving no chronic medications. we now routinely test patients with hypocortisolism or hypercortisolism in our clinic and ward.

Keywords: corticotropin releasing hormone cushing syndrome psychiatric hypercortisolism adrenal insufficiency normal volunteer
colonoscopic skill acquisition and transfer via simulated curriculum of progressive training

Conditions: Colorectal Cancer

Summary: it is hypothesized that a progressive simulated learning strategy will result in better global clinical performance (e.g., technical, communication) and transfer of endoscopic skill, as compared with a high-fidelity simulation strategy.


Eligibility criteria:
inclusion criteria: * novice endoscopists from adult gastroenterology, pediatric gastroenterology, general surgery training programs at university of toronto exclusion criteria: * trainees who have performed greater than 25 colonoscopies will be excluded to ensure all participants are novices.
evaluation of the effectiveness of montelukast in children with recurrent obstructive bronchitis

Conditions: Acute Bronchiolitis

Summary: the aim of the study was to evaluate the effectiveness of montelukast sodium in the treatment and prevention of recurrent obstructive bronchitis in children. the investigators examined 80 children aged 1 to 7 years with recurrent obstructive bronchitis, who were randomly divided into 2 groups.

the aim of the study was to evaluate the effectiveness of montelukast sodium in the treatment and prevention of recurrent obstructive bronchitis in children. the investigators examined 80 children aged 1 to 7 years with recurrent obstructive bronchitis, who were randomly divided into 2 groups. group i (control) included 40 patients who received standard therapy and placebo. group ii (main) included 40 patients who received standart therapy and oral montelukast sodium.

Eligibility criteria:
inclusion criteria: * rda score=6 points * e:i index score \>1.40 * ineffective treatment at home for ≥48 hours * adverse comorbidities exclusion criteria: * chronic or congenital diseases of the central nervous, cardiovascular and bronchopulmonary systems

Keywords: montelukast sodium prevention relapse obstructive bronchitis
investigation of protein biomarkers of prostate cancer

Conditions: Prostate Cancer

Summary: this study is looking at biomarkers in prostate cancer.

1. to establish primary culture of epithelial cells isolated from prostatectomy samples 2. to study biomarkers in prostate cancer

Eligibility criteria:
inclusion criteria: * patients with prostate cancer.
bed-rest, muscle mass and insulin sensitivity

Conditions: Disuse Atrophy

Summary: in the present study, the effects of 7 days of bed rest on muscle mass, muscle fiber characteristics and insulin sensitivity will be determined.


Eligibility criteria:
inclusion criteria: * male * aged from 18-35 years * 18.5 \< bmi \< 30 kg/m2 exclusion criteria: * smoking * performing regular resistance training (3+ times per week, carrying out progressive training) in the previous 6 months * hypertension (according to who criteria) and/or cardiovascular disease * any back/leg/knee/neck/postural complaints * use of any prescribed medication * type 2 diabetes mellitus * any family history of thrombosis * all co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis). * myocardial infarction within the last 3 years * use of anti-coagulants
an integrative-"omics" study of cardiomyopathy patients for diagnosis and prognosis in china

Conditions: Dilated Cardiomyopathy; Hypertrophic Cardiomyopathy; Arrhythmogenic Right Ventricular Cardiomyopathy; Left Ventricular Non-compaction; Restrictive Cardiomyopathy

Summary: this is a multi-omics research of chinese cardiomyopathies patients, aiming to determine genetic risk factor and serial biomarkers of cardiomyopathies in diagnosis and prognosis.

identification of novel biomarkers is needed to improve the diagnosis and prognosis of cardiomyopathy. also,the marked variation of genes which is still unclear, may influence clinical outcomes is determined in part by genetic heterogeneity of the systemic response to pathological process. specific aim: 1. proteomics, microrna-seq and metabolomics will be to determine the correlation of echocardiographic parameters of systolic and diastolic functional entry with circulating molecules 2. genomics will be to determine the association of clinical outcome

Eligibility criteria:
inclusion criteria: 1. subjects who was diagnosed as cardiomyopathy by medical history, clinical symptoms, laboratory tests including ecg, echocardiography. 2. subject understands study requirements aand agrees to sign an informed consent form prior to any study procedures. exclusion criteria: 1. endocrine disease known to cause heart muscle disease (including infants of diabetic mothers) 2. history of rheumatic fever 3. toxic exposures known to cause heart muscle disease (anthracyclines, mediastinal radiation, iron overload or heavy metal exposure) 4. hiv infection or born to an hiv positive mother 5. kawasaki disease 6. immunologic disease 7. uremia, active or chronic 8. abnormal ventricular size or function that can be attributed to intense 9.physical training or chronic anemia 10.chronic arrhythmia, unless there are studies documenting inclusion criteria prior to the onset of arrhythmia (except a patient with chronic arrhythmia, subsequently ablated, whose cardiomyopathy persists after two months is not to be excluded) 11.malignancy 12.pulmonary parenchymal or vascular disease (e.g., cystic fibrosis, cor pulmonale, or pulmonary hypertension) 13.ischemic coronary vascular disease 14.association with drugs (e.g., growth hormone, corticosteroids, cocaine) or other diseases known to cause hypertrophy
selective serotonin reuptake inhibitors (ssris) in borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: the goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (ssri) escitalopram (also known by the trade name "lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. subjects will receive either escitalopram or placebo for eight weeks. during this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.


Eligibility criteria:
inclusion criteria: * diagnosis of borderline personality disorder * current major depression exclusion criteria: * past 2 months ssri use * past 6 months non-ssri antidepressant use * past 2 months initiation of psychotherapy * lifetime bipolar disorder, organic disorder, psychotic disorder * current alcohol or drug dependence * current severe suicidal / homicidal ideation necessitating immediate medical intervention * currently pregnancy or nursing * unable or unwilling to cooperate with study protocol

Keywords: selective serotonin reuptake inhibitor escitalopram borderline personality disorder major depressive disorder self-harm
regn7257 in adult patients with severe aplastic anemia that is refractory to or relapsed on immunosuppressive therapy

Conditions: Severe Aplastic Anemia (SAA)

Summary: this study is researching an experimental drug called regn7257 (called "study drug"). the study is focused on patients who have severe aplastic anemia (saa), a disease of the bone marrow resulting in an impairment of the production of blood cells. the main purpose of this two-part study (part a and part b) is to test how safe and tolerable regn7257 is in patients with saa in which other immunosuppressive therapies (ists) have not worked well. the study is looking at several other research questions to better understand the following properties of regn7257: * side effects that may be experienced by participants taking regn7257 * how regn7257 works in the body * how much regn7257 is present in blood after dosing * if regn7257 works to raise levels of certain blood counts after treatment * how quickly regn7257 works to raise levels of certain blood counts * in patients for whom regn7257 works to raise levels of certain blood counts after treatment, how many continue to show such a response throughout the study * if regn7257 works to lower the number of platelet and red blood cell transfusions needed * how regn7257 changes immune cell counts and composition * how the body reacts to regn7257 and if it produces proteins that bind to regn7257 (this would be called the formation of anti-drug antibodies \[ada\])


Eligibility criteria:
key inclusion criteria: 1. part a: saa that is ist-refractory or ist-relapsed, as defined in the protocol 2. part b: saa that is ist-relapsed, as defined in the protocol 3. hematopoietic stem cell transplantation (hsct) is not available or suitable as a treatment option or has been refused by the patient 4. adequate hepatic and renal function as defined in the protocol key exclusion criteria: 1. diagnosis of fanconi anemia or other congenital bone marrow failure syndrome as defined in the protocol 2. evidence of myelodysplastic syndrome as defined in the protocol 3. paroxysmal nocturnal hemoglobinuria (pnh) with evidence of clinically significant hemolysis (eg, treatment indicated) or history of pnh-associated thrombosis 4. treatment with a t cell-depleting agent (eg, atg or alemtuzumab) within 6 months prior to dosing 5. treatment with a calcineurin inhibitor (eg, cyclosporine) within 4 weeks prior to dosing for patients enrolled in part a 6. treatment with eltrombopag or investigational thrombopoietin receptor agonist, granulocyte colony-stimulating factor (g-csf), or an androgen (eg, danazol), within 2 weeks prior to dosing 7. hiv, hepatitis b or hepatitis c positive by serological testing at the screening visit as defined in the protocol 8. active tuberculosis, latent tuberculosis infection (ltbi) or history incompletely-treated tuberculosis or ltbi 9. active infection as defined in the protocol note: other protocol-defined inclusion/ exclusion criteria apply

Keywords: immunosuppressive therapy (ist) refractory relapsed
combined use of angiography, optical coherence tomography and intravascular ultrasound in evaluation of pulmonary vascular structure and function in patients with pulmonary arterial hypertension treated with oral bosentan

Conditions: Pulmonary Arterial Hypertension

Summary: it has been hypothesized that one of the benefits of bosentan relates to pulmonary vascular remodeling. the investigators believe that this study will help document the nature of beneficial changes that occur in patients with pulmonary arterial hypertension (pah) in response to bosentan therapy. in turn, demonstrating that changes in pulmonary vascular structure and function accompany clinical improvement.

subjects will have optical coherence tomography (oct) and intravascular ultrasound (ivus) imaging during the right heart catheterization that diagnoses them as having pah. subjects will start their bosentan and will be followed by monthly clinic visits for 4 months. at 4 months they will have repeat oct and ivus imaging.

Eligibility criteria:
inclusion criteria: 1. who group 1 2. age 18-75 3. baseline 6-min walk distance (6mwd) between 200 and 450 m 4. diagnosed with pulmonary artery hypertension during right heart catheterization (mean pulmonary artery pressure \> 25mmhg) general exclusion criteria 1. pregnant or nursing 2. acute or chronic illness other than those associated with pah (collagen vascular disease, human immunodeficiency virus, or anorexigen use) 3. previously received any investigational medications, prostanoids, or phosphodiesterase inhibitors 4. egfr \< 60 5. angina 6. syncope 7. failing right ventricle 8. hemoptysis
a non interventional study with irinotecan onkovis (irinotecan) utilized for the treatment of cancer

Conditions: Carcinoma

Summary: the main purpose of this observational study with irinotecan onkovis is to determine the number of treatment cycles and the quantity of irinotecan onkovis needed for this purpose under the special circumstances of ambulant chemotherapy. onkovis aims to contribute to an economical utilization of the chemotherapeutics. this includes provision of appropriate packaging sizes to decrease the excess quantity to be discarded, and thus also follows this objective. secondary objective is the assessment of the side effects of irinotecan onkovis. to this end, data regarding co-medication and adverse events are also collected.


Eligibility criteria:
inclusion criteria: * indication for irinotecan according to the smpc and treating physician exclusion criteria: * according to the irinotecan smpc

Keywords: carcinoma colorectal cancer ambulant chemotherapy treatment cycles irinotecan irinotecan onkovis quantity of irinotecan packaging sizes